GSK is moving its B7-H4–targeting antibody-drug conjugate, licensed from Hansoh Pharma, into a major late-stage push with plans for five Phase 3 trials, largely focused on gynecologic cancers such as ovarian and endometrial disease. The program reflects GSK’s growing commitment to ADCs, aiming to position the asset across multiple treatment settings and combinations as a potential new option for patients with hard-to-treat tumors. Find out more details in 2 news articles below.